An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Miravo Healthcare™ Announces Participation at the H.C. Wainwright Bioconnect Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) will present at the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The virtual event will feature Jesse Ledger, President & CEO, and Mary-Jane Burkett, VP & CFO, discussing the Company’s business overview. Interested investors can access the presentation starting at 7:00 a.m. ET on January 10. The Company focuses on healthcare products in areas like pain and allergy, supported by its operations in Canada and Ireland.
Positive
Feature presentation at a significant investor conference highlights company visibility.
Leadership involvement indicates a proactive approach to engage with investors.
Negative
None.
- January 10-13, 2022 (Virtual Conference) -
MISSISSAUGA, Ontario--(BUSINESS WIRE)--
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it will be featured as a presenting company at the H.C. Wainwright Bioconnect Conference. The conference is being held as a virtual conference on January 10-13, 2022.
Jesse Ledger, Miravo’s President & Chief Executive Officer and Mary-Jane Burkett, Miravo’s Vice President & Chief Financial Officer, will be providing an overview of the Company's business during the presentation. If you are an institutional or retail investor and would like to listen to the Company’s presentation, please click on the following link (https://hcwevents.com/bioconnect/) to register for the conference. Corporate presentations and panels are available live and on-demand on January 10, 2022, starting at 7:00 a.m. ET.
H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com.
About Miravo Healthcare
Miravo is a Canadian-focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company’s products target several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S., Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.
